Gathering the record
Relay is organizing the evidence and source boundaries.
Selective, long-acting amylin receptor agonist
Eloralintide is an investigational once-weekly selective amylin receptor agonist being studied for obesity. A 48-week randomized Phase 2 trial reported substantial average weight reduction across several studied arms, and a broad Phase 3 ENLIGHTEN program is underway. It is not FDA approved.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Eloralintide is an investigational, long-acting medicine designed to act selectively on one amylin-related receptor involved in fullness and appetite regulation.
Researchers want to know whether more selective amylin signaling can support weight management while producing a different effect or tolerability pattern from other amylin medicines and incretin-based treatments.
A peer-reviewed 48-week Phase 2 trial reported substantial average weight reduction across several studied arms in adults without type 2 diabetes. Earlier trials supported weekly exposure and short-term signals; nausea and fatigue varied across arms.
Large Phase 3 confirmation, rare harms, long-term durability, and results in diabetes, sleep apnea, knee osteoarthritis, or add-on settings remain unresolved. Eloralintide is not approved, and no public generic-vial handling standard exists.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A published Phase 2 trial investigated eloralintide in adults with obesity or overweight plus a related condition who did not have type 2 diabetes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Published Phase 1 and 48-week Phase 2 trials are joined by a broad active Phase 3 program.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The controlled weight signal is substantial, but pivotal replication, rare-event safety, and durability remain pending.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trial included several distinct study arms; they do not form one transferable sequence. Phase 2 results do not establish Phase 3 benefit, approval, or preparation rules for independently sourced material. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 263-participant randomized, double-blind Phase 2 trial reported mean 48-week body-weight reductions ranging from 9% to 20% across studied eloralintide arms versus 0.4% with placebo under the efficacy estimand.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether the large ENLIGHTEN Phase 3 trials confirm long-term efficacy, tolerability, rare-event safety, durability, and benefit in diabetes, sleep apnea, osteoarthritis, and incretin add-on settings.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The ENLIGHTEN Phase 3 program is recruiting across obesity and related populations. No FDA-approved eloralintide product label, consumer dose, or official handling instructions were identified.
In-vitro discovery work reported roughly 12-fold greater potency at human AMY1R than at the calcitonin receptor and roughly 11-fold greater potency than at AMY3R.
Mean change under the efficacy estimand ranged from -9% to -20% across studied eloralintide arms versus -0.4% with placebo.
The 100-participant multiple-dose study reported a roughly two-week half-life range and mean 12-week weight reductions across cohorts, while an earlier single-dose study supported progression into weekly development.
Nausea ranged from 11% to 64% across eloralintide arms and fatigue from 0% to 46%, compared with 14% and 12% with placebo, respectively.
These registrations show the breadth of the development program and the outcomes researchers plan to measure.
The study records document protocol-specific doses, escalation schemes, eligibility, and sponsor-controlled injections to explain how research was conducted.
Official trial records describe sponsor-controlled investigational injections rather than a marketed consumer product or general handling method.
Eloralintide has a distinct receptor-selectivity profile and its current monotherapy evidence comes from its own trials. Add-on and combination programs remain separate evidence records.
Mechanisms
Eloralintide (LY3841136) is a lipidated, long-acting amylin analogue designed for preferential human AMY1R activation with lower in-vitro potency at AMY3R and the calcitonin receptor. Published human evidence includes a 48-participant single-ascending-dose study, a 100-participant multiple-ascending-dose study, and a 263-participant 48-week randomized Phase 2 obesity trial. Phase 3 studies are evaluating obesity with and without type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity during stable incretin therapy. These registered studies have no posted outcome results at the current cutoff.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, placebo-controlled, participant- and investigator-blinded multiple ascending-dose study
Adults with obesity or overweight without diabetes
Exposure was approximately dose proportional, and mean body-weight reduction across eloralintide cohorts ranged from 2.6% to 11.3% at week 12. Decreased appetite, headache, and fatigue were among the most common reported events.
Study administration: Once-weekly subcutaneous eloralintide across five dose cohorts without within-participant escalation, or placebo
Limitations: This was a short, early-phase dose-cohort study with small groups and exploratory pharmacodynamic outcomes. It cannot establish long-term efficacy, comparative effectiveness, or rare safety.
Multicenter, double-blind, randomized, placebo-controlled parallel-group trial
Adults with obesity, or overweight plus at least one weight-related comorbidity, without type 2 diabetes
At week 48, mean body-weight change under the efficacy estimand ranged from -9% to -20% across eloralintide arms versus -0.4% with placebo. Nausea and fatigue were the most common adverse events, with rates varying substantially by arm.
Study administration: Once-weekly subcutaneous eloralintide across fixed-dose and dose-escalation arms, or placebo
Limitations: This sponsor-funded dose-ranging trial excluded type 2 diabetes and used relatively small individual arms. Its studied doses and escalation schemes are research methods, not approved dosing guidance, and group averages are not individual predictions.
Randomized, placebo-controlled, participant- and investigator-blinded single-dose study with translational preclinical experiments
Healthy adults in the clinical portion
The translational study reported preferential human AMY1R activation over calcitonin and AMY3 receptors in vitro. In the clinical portion, selected higher single-dose cohorts had larger mean week-4 weight reductions than placebo.
Study administration: Single subcutaneous eloralintide doses or placebo
Limitations: The receptor findings came from assays and animal models, while the human study was small, single-dose, and performed in healthy participants. It cannot establish receptor-specific clinical benefit or long-term obesity outcomes.
Randomized, double-blind, placebo-controlled parallel study
Adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes
ENLIGHTEN-1 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.
Study administration: Once-weekly subcutaneous eloralintide or placebo
Limitations: The registration describes planned methods and outcomes. It does not establish efficacy, safety, or diabetes prevention.
Randomized, double-blind, placebo-controlled parallel study
Adults with obesity or overweight and type 2 diabetes
ENLIGHTEN-2 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.
Study administration: Once-weekly subcutaneous eloralintide or placebo
Limitations: The registry establishes the study question, not whether eloralintide improves weight, glucose, or safety outcomes in type 2 diabetes.
Two randomized, double-blind, placebo-controlled studies within one knee-osteoarthritis program
Adults with obesity or overweight and symptomatic knee osteoarthritis
ENLIGHTEN-4 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.
Study administration: Once-weekly subcutaneous eloralintide or placebo
Limitations: The registration does not demonstrate pain relief, improved function, or whether any future change would be mediated by weight loss or another pathway.
Randomized, double-blind, placebo-controlled parallel study
Adults with persistent obesity or overweight despite stable weekly incretin background therapy, with or without type 2 diabetes
ENLIGHTEN-6 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.
Study administration: Once-weekly subcutaneous eloralintide or placebo added to stable weekly incretin therapy
Limitations: This add-on study cannot be used to claim benefit, safety, or compatibility before results are available. It also does not provide self-directed combination guidance.
Two randomized, double-blind, placebo-controlled studies within one obstructive-sleep-apnea program
Adults with moderate-to-severe obstructive sleep apnea and obesity or overweight, with separate PAP-use contexts
ENLIGHTEN-3 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.
Study administration: Once-weekly subcutaneous eloralintide or placebo
Limitations: No outcome can be inferred from an active registration. Weight change alone would also not establish a direct sleep-apnea effect without the prespecified trial results.
Safety snapshot
Nausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.
Controlled human evidenceOne 263-participant trial cannot define rare, long-term, or population-wide safety. Phase 3 safety results remain pending.
Open sourceNausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.
Controlled human evidenceThe stated frequency is source-, product-, population-, route-, dose-, comparator-, and duration-specific; it is not a universal incidence estimate.
Open sourceNo source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational; Phase 3 ENLIGHTEN program active, with no FDA-approved eloralintide product Whether the large ENLIGHTEN Phase 3 trials confirm long-term efficacy, tolerability, rare-event safety, durability, and benefit in diabetes, sleep apnea, osteoarthritis, and incretin add-on settings.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-17 · NCT07321886
2026-06-23 · NCT07282600
2026-06-23 · NCT07353931
2026-06-23 · NCT07392190
2026-06-04 · NCT07369011
2026-01-20 · PMID 41559929 · NCT05295940 · DOI 10.1111/dom.70439
2025-11-06 · PMID 41207310 · NCT06230523 · DOI 10.1016/S0140-6736(25)02155-5
2025-10-16 · PMID 41109426 · NCT05295940 · DOI 10.1016/j.molmet.2025.102271